Activation of cell cycle arrest and apoptosis by the proto-oncogene Pim-2

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Levy, Daphna ^a   Davidovich, Ateret ^a   Zirkin, Shahar ^a   Frug, Yulia ^a   Cohen, Amos M ^b   Shalom, Sara ^a   Don, Jeremy ^a  

^a BAR ILAN UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CYCLIN DEPENDENT KINASE 2; PROTEIN CDC25A; PROTEIN P57; PROTEIN P73; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; CDC25A PROTEIN, HUMAN; CDKN1C PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1C; DNA BINDING PROTEIN; ISOPROTEIN; NUCLEAR PROTEIN; ONCOPROTEIN; PIM2 PROTEIN, HUMAN; PROTEASOME; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE PHOSPHATASE; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; GENE FUNCTION; GENE LOCATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN CELL; MOLECULAR SIZE; PIM 2 GENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTO ONCOGENE; UPREGULATION; CELL LINE; CELL STRAIN HCT116; CELL STRAIN HEK293; CELL STRAIN HL 60; CELL STRAIN HT29; CELL SURVIVAL; EXPERIMENTAL MELANOMA; G1 PHASE CELL CYCLE CHECKPOINT; GENETICS; HELA CELL; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

APOPTOSIS; CDC25 PHOSPHATASES; CELL LINE; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P57; CYTOPLASM; DNA-BINDING PROTEINS; DOWN-REGULATION; E2F1 TRANSCRIPTION FACTOR; G1 PHASE CELL CYCLE CHECKPOINTS; HCT116 CELLS; HEK293 CELLS; HELA CELLS; HL-60 CELLS; HT29 CELLS; HUMANS; MELANOMA, EXPERIMENTAL; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN ISOFORMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 84859562229     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034736     Document Type: Article

References (64)

1. Wang Z, Bhattacharya N, Weaver M, Petersen K, Meyer M, et al. (2001) Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci 2: 167-179.
2. Allen JD, Verhoeven E, Domen J, van der Valk M, Berns A, (1997) Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene 15: 1133-1141.
3. Bachmann M, Moroy T, (2005) The serine/threonine kinase Pim-1. Int J Biochem Cell Biol 37: 726-730.
4. Cuypers HT, Selten G, Quint W, Zijlstra M, Maandag ER, et al. (1984) Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 37: 141-150.
5. van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, et al. (1989) Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 56: 673-682.
6. Moroy T, Verbeek S, Ma A, Achacoso P, Berns A, et al. (1991) E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice. Oncogene 6: 1941-1948.
7. Laird PW, van der Lugt NM, Clarke A, Domen J, Linders K, et al. (1993) In vivo analysis of Pim-1 deficiency. Nucleic Acids Res 21: 4750-4755.
8. van der Lugt NM, Domen J, Verhoeven E, Linders K, van der GH, et al. (1995) Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2. EMBO J 14: 2536-2544.
9. Mikkers H, Nawijn M, Allen J, Brouwers C, Verhoeven E, et al. (2004) Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 24: 6104-6115.
10. Cohen AM, Grinblat B, Bessler H, Kristt D, Kremer A, et al. (2004) Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma 45: 951-955.
11. Chen JL, Limnander A, Rothman PB, (2008) Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene. Blood 111: 1677-1685.
12. Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS, (2005) Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res 3: 443-451.
13. Dai H, Li R, Wheeler T, Diaz de Vivar A, Frolov A, et al. (2005) Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate 65: 276-286.
14. Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA, et al. (2003) The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev 17: 1841-1854.
15. Yan B, Zemskova M, Holder S, Chin V, Kraft A, et al. (2003) The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem 278: 45358-45367.
16. Macdonald A, Campbell DG, Toth R, McLauchlan H, Hastie CJ, et al. (2006) Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biol 7: 1.
17. Hammerman PS, Fox CJ, Cinalli RM, Xu A, Wagner JD, et al. (2004) Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappaB activation. Cancer Res 64: 8341-8348.
18. Peng C, Knebel A, Morrice NA, Li X, Barringer K, et al. (2007) Pim kinase substrate identification and specificity. J Biochem (Tokyo) 141: 353-362.
19. Zhang Y, Wang Z, Li X, Magnuson NS, (2008) Pim kinase-dependent inhibition of c-Myc degradation. Oncogene 27: 4809-4819.
20. Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N, (2008) Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res 68: 5076-5085.
21. Chen LS, Redkar S, Bearss D, Wierda WG, Gandhi V, (2009) Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 114: 4150-4157.
22. Baytel D, Shalom S, Madgar I, Weissenberg R, Don J, (1998) The human Pim-2 proto-oncogene and its testicular expression. Biochim Biophys Acta 1442: 274-285.
23. Amaravadi R, Thompson CB, (2005) The survival kinases Akt and Pim as potential pharmacological targets. J Clinic Invest 115: 2618-2624.
24. Ionov Y, Le X, Tunquist BJ, Sweetenham J, Sachs T, et al. (2003) Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear localization is necessary for its biologic effects. Anticancer Res 23: 167-178.
25. Muraski JA, Rota M, Misao Y, Fransioli J, Cottage C, et al. (2007) Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med 13: 1467-1475.
26. Donzelli M, Draetta GF, (2003) Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep 4: 671-677.
27. Busino L, Chiesa M, Draetta GF, Donzelli M, (2004) Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene 23: 2050-2056.
28. Ginsberg D, (2002) E2F1 pathways to apoptosis. FEBS Lett 529: 122-125.
29. Hiebert SW, Packham G, Strom DK, Haffner R, Oren M, et al. (1995) E2F-1:DP-1 induces p53 and overrides survival factors to trigger apoptosis. Mol Cell Biol 15: 6864-6874.
30. Powers JT, Hong S, Mayhew CN, Rogers PM, Knudsen ES, et al. (2004) E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis. Mol Cancer Res 2: 203-214.
31. Hershko T, Chaussepied M, Oren M, Ginsberg D, (2005) Novel link between E2F and p53: proapoptotic cofactors of p53 are transcriptionally upregulated by E2F. Cell Death Differ 12: 377-383.
32. Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, et al. (2000) Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407: 645-648.
33. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW, (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16-23.
34. Nawijn MC, Alendar A, Berns A, (2011) For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 11: 23-34.
35. Lin YW, Beharry ZM, Hill EG, Song JH, Wang W, et al. (2010) A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood 115: 824-833.
36. Hiromura K, Pippin JW, Blonski MJ, Roberts JM, Shankland SJ, (2002) The subcellular localization of cyclin dependent kinase 2 determines the fate of mesangial cells: role in apoptosis and proliferation. Oncogene 21: 1750-1758.
37. Golsteyn RM, (2005) Cdk1 and Cdk2 complexes (cyclin dependent kinases) in apoptosis: a role beyond the cell cycle. Cancer Lett 217: 129-138.
38. De Clercq A, Inze D, (2006) Cyclin-dependent kinase inhibitors in yeast, animals, and plants: a functional comparison. Crit Rev Biochem Mol Biol 41: 293-313.
39. Li G, Domenico J, Lucas JJ, Gelfand EW, (2004) Identification of multiple cell cycle regulatory functions of p57Kip2 in human T lymphocytes. J Immunol 173: 2383-2391.
40. Scandura JM, Boccuni P, Massague J, Nimer SD, (2004) Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. Proc Natl Acad Sci USA 101: 15231-15236.
41. Samuelsson MK, Pazirandeh A, Davani B, Okret S, (1999) p57Kip2, a glucocorticoid-induced inhibitor of cell cycle progression in HeLa cells. Mol Endocrinol 13: 1811-1822.
42. Samuelsson MK, Pazirandeh A, Okret S, (2002) A pro-apoptotic effect of the CDK inhibitor p57(Kip2) on staurosporine-induced apoptosis in HeLa cells. Biochem Biophys Res Commun 296: 702-709.
43. Vlachos P, Nyman U, Hajji N, Joseph B, (2007) The cell cycle inhibitor p57(Kip2) promotes cell death via the mitochondrial apoptotic pathway. Cell Death Differ 14: 1497-1507.
44. Boutros R, Dozier C, Ducommun B, (2006) The when and wheres of CDC25 phosphatases. Curr Opin Cell Biol 18: 185-191.
45. Bartek J, Lukas C, Lukas J, (2004) Checking on DNA damage in S phase. Nat Rev Mol Cell Biol 5: 792-804.
46. Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, et al. (1999) Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem 274: 18659-18666.
47. Delavaine L, La Thangue NB, (1999) Control of E2F activity by p21Waf1/Cip1. Oncogene 18: 5381-5392.
48. Coqueret O, Gascan H, (2000) Functional interaction of STAT3 transcription factor with the cell cycle inhibitor p21WAF1/CIP1/SDI1. J Biol Chem 275: 18794-18800.
49. Vigneron A, Cherier J, Barre B, Gamelin E, Coqueret O, (2006) The cell cycle inhibitor p21waf1 binds to the myc and cdc25A promoters upon DNA damage and induces transcriptional repression. J Biol Chem 281: 34742-34750.
50. Moroni MC, Hickman ES, Lazzerini DE, Caprara G, Colli E, et al. (2001) Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol 3: 552-558.
51. Melino G, Bernassola F, Ranalli M, Yee K, Zong WX, et al. (2004) p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem 279: 8076-8083.
52. Ramadan S, Terrinoni A, Catani MV, Sayan AE, Knight RA, et al. (2005) p73 induces apoptosis by different mechanisms. Biochem Biophys Res Commun 331: 713-717.
53. Blint E, Phillips AC, Kozlov S, Stewart CL, Vousden KH, (2002) Induction of p57(KIP2) expression by p73beta. Proc Natl Acad Sci USA 99: 3529-3534.
54. Gonzalez S, Perez-Perez MM, Hernando E, Serrano M, Cordon-Cardo C, (2005) p73beta-Mediated apoptosis requires p57kip2 induction and IEX-1 inhibition. Cancer Res 65: 2186-2192.
55. Guo G, Qiu X, Wang S, Chen Y, Rothman PB, et al. (2010) Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells. Oncogene 29: 3845-3853.
56. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW, (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16-23.
57. Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, et al. (1996) Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA 93: 4816-4820.
58. Trainer DL, Kline T, McCabe FL, Faucette LF, Feild J, et al. (1988) Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int J Cancer 41: 287-296.
59. Graham FL, Smiley J, Russell WC, Nairn R, (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36: 59-74.
60. Pratt SE, Pollak MN, (1993) Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res 53: 5193-5198.
61. Koeffler HP, Golde DW, (1980) Human myeloid leukemia cell lines: a review. Blood 56: 344-350.
62. Epstein MA, Achong BG, Barr YM, Zajac B, Henle G, et al. (1966) Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji). J Natl Cancer Inst 37: 547-559.
63. Yonezawa Y, Hada T, Uryu K, Tsuzuki T, Nakagawa K, et al. (2007) Mechanism of cell cycle arrest and apoptosis induction by conjugated eicosapentaenoic acid, which is a mammalian DNA polymerase and topoisomerase inhibitor. Int J Oncol 30: 1197-1204.
64. Gil S, Yosef D, Golan N, Don J, (2006) The enigma of ATCE1, an acrosome-associated transcription factor. Dev Biol 298: 201-211.